Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer

Kudlacek, St.; Schieder, K.; Kölbl, H.; Neunteufel, W.; Nowotny, Ch.; Breitenecker, G.; Biegelmayer, G; Vetterlein, M.; Furlinger, B; Micksche, M.

doi:10.1016/0090-8258(89)90072-3

Cited by 17 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, some normal body tissues can produce a certain and low level of circulatory or serum CA125. This tumor marker is found elevated during menstruation or pregnancy and in some benign conditions such as endometriosis, peritonitis or cirrhosis, particularly with ascites [13, 14]. It is also increased in vascular invasion, tissue destruction and inflammation associated with malignant disease.…”

Section: Discussionmentioning

confidence: 99%

Meigs’ Syndrome with Elevated Serum CA125: Case Report and Review of the Literature

Benjapibal

Sangkarat²,

Laiwejpithaya³

et al. 2009

Case Rep Oncol

View full text Add to dashboard Cite

An elevated serum CA125 level in association with a pelvic mass, pleural effusion, and massive ascites usually signifies a dismal prognosis in a postmenopausal woman. However, surgery and histopathological examination are required for the correct diagnosis and treatment, since an elevated CA125 level can be falsely positive for ovarian malignancy. We present a case of Meigs’ syndrome due to right ovarian fibroma with elevated CA125 level in a postmenopausal woman.

show abstract

Section: Discussionmentioning

confidence: 99%

Meigs’ Syndrome with Elevated Serum CA125: Case Report and Review of the Literature

Benjapibal

Sangkarat²,

Laiwejpithaya³

et al. 2009

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“… 82 Alternatively, a study of 1,043 Han Chinese patients reported that the G allele of the same polymorphism was significantly associated with high-risk PDR in type 2 diabetes ( P =0.02), although no association was reported with NDPR. 83 Two subsequent studies of 758 Japanese patients with type 2 diabetes ( P =0.030) 84 and 517 Han Chinese patients with type 2 diabetes ( P =0.026) 85 also reported that the G allele, not the A allele, was significantly associated with DR.…”

Section: Newer Candidate Genesmentioning

confidence: 99%

Update on genetics and diabetic retinopathy

Hampton

Schwartz

Brantley

et al. 2015

OPTH

View full text Add to dashboard Cite

Clinical risk factors for diabetic retinopathy (DR), such as duration of disease and degree of glucose control, do not adequately predict disease progression in individual patients, suggesting the presence of a genetic component. Multiple smaller studies have investigated genotype–phenotype correlations in genes encoding vascular endothelial growth factor, aldose reductase, the receptor for advanced glycation end products, and many others. In general, reported results have been conflicting, due to factors including small sample sizes, variations in study design, differences in clinical end points, and underlying genetic differences between study groups. At this time, there is no confirmed association with any risk allele reported. As we continue to collect data from additional studies, the role of genetics in DR may become more apparent.

show abstract

“…The reactive antigen was subsequently found to be elevated in the sera of a majority of ovarian cancer patients which formed the basis of a radioimmunoassay test [5, 9, 10] (Figure 1). CA125 was found to be a sensitive biomarker for ovarian cancer patients in specific contexts [11, 12, 13]. Setting the benchmark cutoff of 35U/ml, it was found that 1% of normal women had elevated CA125, while 6% of those with benign disease and 28% of those with non-gynecological cancers had elevated antigen levels.…”

Section: Historymentioning

confidence: 99%

MUC16 as a novel target for cancer therapy

Aithal

Rauth

Kshirsagar

et al. 2018

Expert Opinion on Therapeutic Targets

177

141

View full text Add to dashboard Cite

MUC16 is overexpressed in multiple cancers and plays an important role in tumorigenicity and acquired resistance to therapy. Area covered: In this review, we describe the role of MUC16 under normal physiological conditions and during tumorigenesis. First, we provide a summary of research on MUC16 from its discovery as CA125 to present anti-MUC16 therapy trials that are currently in the initial phases of clinical testing. Finally, we discuss the reasons for the limited effectiveness of these therapies and discuss the direction and focus of future research. Expert opinion: Apart from its protective role in normal physiology, MUC16 contributes to disease progression and metastasis in several malignancies. Due to its aberrant overexpression, it is a promising target for diagnosis and therapy. Cleavage and shedding of its extracellular domain is the major barrier for efficient targeting of MUC16-expressing cancers. Concerted efforts should be undertaken to target the noncleaved cell surface retained portion of MUC16. Such efforts should be accompanied by basic research to understand MUC16 cleavage and decipher the functioning of MUC16 cytoplasmic tail. While previous efforts to activate anti-MUC16 immune response using anti-CA125 idiotype antibodies have met with limited success, ideification of neo-antigenic epitopes in MUC16 that correlate with improved survival have raised raised hopes for developing MUC16-targeted immunotherapy.

show abstract

Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer

Cited by 17 publications

References 18 publications

Meigs’ Syndrome with Elevated Serum CA125: Case Report and Review of the Literature

Meigs’ Syndrome with Elevated Serum CA125: Case Report and Review of the Literature

Update on genetics and diabetic retinopathy

MUC16 as a novel target for cancer therapy

Contact Info

Product

Resources

About